Clinical trial
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00310180
Study timeline
Study start (actual)2006-04-07Date precision: day
Registry last updated2026-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Adenocarcinomaunresolved
Hormone Receptor Positiveunresolved
Stage IA Breast Cancer AJCC v7unresolved
Stage IB Breast Cancer AJCC v7unresolved
Stage IIA Breast Cancer AJCC v6 and v7unresolved
Stage IIB Breast Cancer AJCC v6 and v7unresolved
Stage IIIB Breast Cancer AJCC v7unresolved
Interventions
AnastrozoleDRUG · verified · RxNorm: anastrozole
ExemestaneDRUG · verified · RxNorm: exemestane
LetrozoleDRUG · verified · RxNorm: letrozole
Radiation TherapyRADIATION
Tamoxifen CitrateDRUG · verified · RxNorm: tamoxifen citrate
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
American College of Surgeonscollaborator
Cancer and Leukemia Group Bcollaborator
NSABP Foundation Inccollaborator
NCIC Clinical Trials Groupcollaborator
North Central Cancer Treatment Groupcollaborator
SWOG Cancer Research Networkcollaborator
Mapped research locations
ChicagoIllinois, United States13St LouisMissouri, United States9New YorkNew York, United States8PhiladelphiaPennsylvania, United States8BaltimoreMaryland, United States8NashvilleTennessee, United States8PortlandOregon, United States8Kansas CityMissouri, United States8HonoluluHawaii, United States8OmahaNebraska, United States7ToledoOhio, United States7Des MoinesIowa, United States7
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00310180 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.